FOLH1 and prostate cancer: The introduction of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) has enabled a more sensitive and specific appraisal of disease extent in men with prostate cancer [8,9].